Free Trial

Keros Therapeutics (KROS) SEC Filings & 10K Form

$52.51
-1.17 (-2.18%)
(As of 09/6/2024 ET)

Recent Keros Therapeutics SEC Filings

DateFilerForm TypeView
09/03/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/28/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/15/2024
4:06 PM
GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2024
4:01 PM
Keros Therapeutics (Issuer)
ORBIMED ADVISORS LLC (Reporting)
OrbiMed Capital GP VII LLC (Reporting)
OrbiMed Genesis GP LLC (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:12 PM
Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/07/2024
3:02 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
4:15 PM
Keros Therapeutics (Filer)
Form 424B5
06/17/2024
4:17 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
5:07 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
3:10 PM
BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
06/05/2024
3:11 PM
BIENAIME JEAN JACQUES (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/03/2024
3:15 PM
Farzan Nima (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
GORDON CARL L (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
GRAY MARY ANN (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Knowles Julius (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Nussbaum Ran (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Kariv Tomer (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
3:15 PM
Keros Therapeutics (Issuer)
Seth Alpna (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/08/2024
7:03 AM
Keros Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/03/2024
7:00 AM
Keros Therapeutics (Filer)
Form S-3ASR
03/14/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2024
7:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/28/2024
3:02 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/15/2024
7:37 PM
Cooper Simon Peter (Reporting)
Keros Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
7:38 PM
Keros Therapeutics (Issuer)
Rovaldi Christopher (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
7:40 PM
Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/15/2024
7:41 PM
Keros Therapeutics (Issuer)
Seehra Jasbir (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2024
5:38 PM
ALKEON CAPITAL MANAGEMENT LLC (Filed by)
Keros Therapeutics (Subject)
Form SC 13G/A
02/09/2024
8:16 AM
FMR LLC (Filed by)
Keros Therapeutics (Subject)
Form SC 13G/A
01/26/2024
4:26 PM
BlackRock Inc. (Filed by)
Keros Therapeutics (Subject)
Form SC 13G/A
01/09/2024
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2024
3:43 PM
Keros Therapeutics (Issuer)
Regnante Keith (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:02 PM
Keros Therapeutics (Filer)
Form 424B5
01/04/2024
3:04 PM
Keros Therapeutics (Subject)
Regnante Keith (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/04/2024
3:04 PM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/03/2024
7:04 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Say Goodbye to the US Dollar (Ad)

The warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late...

12/13/2023
4:20 PM
Keros Therapeutics (Subject)
ORBIMED ADVISORS LLC (Filed by)
Form SC 13D/A
12/11/2023
5:44 PM
Keros Therapeutics (Subject)
ORBIMED CAPITAL LLC (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2023
5:02 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/07/2023
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2023
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2023
7:06 AM
Keros Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2023
7:11 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/04/2023
7:01 AM
Keros Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:KROS) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners